BMKDF
Biomark Diagnostics Inc.

BioMark Diagnostics Inc. offers advanced liquid biopsy platform for early cancer detection, monitoring, and treatment planning through quantitative and qualitative assays that deliver actionable clinical insights. Key Products and Services SSAT1 Assay A quantitative urine-based test that measures N-acetylamantadine (NAA) produced in response to amantadine. Elevated NAA levels reflect overexpression of the SSAT enzyme, aiding early detection of cancers such as lung, breast, prostate, and glioblastoma. Metabolic Panel A qualitative and quantitative assay using metabolomic profiling to identify cancer-specific metabolic signatures. This enhances diagnostic accuracy and informs clinicians about disease presence and progression risk. AI-Enhanced Diagnostics Integrates machine learning to analyze complex metabolic data, improving prediction accuracy for early detection, therapy response, and recurrence monitoring. Additional Activities BioMark conducts ongoing clinical trials and provides educational resources for clinicians and the public to highlight the value of early detection and the science behind its liquid biopsy platform.

BioMark has two principal facilities in Canada. Its head office is located in Richmond, British Columbia, and its fully equipped laboratory is in Quebec City, Quebec. The lab is staffed by a highly skilled technical team and features the latest equipment and robotics to enhance workflow, minimize sample handling errors, and provide high-throughput capabilities. The lab is currently undergoing certification and accreditation to offer medical oncology-related solutions to medical communities.